EUVIMEDEUVIMED entdecken
Crossref

Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs

Julie Barberio, Timothy L Lash, Ajay K Nooka, Ashley I Naimi, Rachel E Patzer, Christopher Kim

Acta Haematologica · 2024

DOI: 10.1159/000539127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Julie Barberio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunomodulating Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Most multiple myeloma (MM) patients experience cytopenias, likely driven by both disease and treatment-related factors. Immunomodulatory agents (IMiDs), which form the backbone of most anti-myeloma regimens, are known to cause higher grade cytopenias. In this context, the impact of sequential IMiD treatments on cytopenia risk is unknown.

Methods

We evaluated the cumulative risks of severe cytopenias following second line of therapy (LOT) initiation in 5,573 MM patients in the Flatiron Health database. Patients for whom both LOTs 1 and 2 contained IMiDs were considered “sequentially exposed”; those for whom neither contained IMiDs were “never exposed.” Results: For the neutropenia outcome, compared to the never exposed, the sequentially exposed had the highest 1-year risk (risk difference [RD] 12%), followed by those only recently exposed during LOT 2 (RD 8%), then by those with only past exposure during LOT 1 (RD 5%). A similar pattern was observed for leukopenia, but no meaningful differences were observed for anemia or thrombocytopenia. The associations between sequential exposure, versus never, with neutropenia and leukopenia were even stronger among those with a recent cytopenia history.

Conclusion

Results suggest that sequential exposure to IMiDs is a risk factor for higher grade cytopenias. These findings have profound clinical implications in choosing newer LOTs with potential risks of cytopenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunomodulating AgentsHumansMaleFemaleAgedMiddle AgedNeutropeniaLeukopeniaRisk FactorsThrombocytopeniaAged, 80 and overAnemiaCytopenia

Stichwörter der Autor:innen

CytopeniaImmunomodulatory drugsMultiple myelomaNeutropenia

Substanzen

Immunomodulating Agents

Autor:innen und Institutionen

  • Department of Epidemiology, Emory University, Atlanta, Georgia, USA.
  • Center for Observational Research, Amgen Inc., Thousand Oaks, California, USA.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Regenstrief Institute, Indianapolis, Indiana, USA.

Zitieren

APA

Barberio, J., Lash, T. L., Nooka, A. K., Naimi, A. I., Patzer, R. E., & Kim, C. (2024). Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs. Acta Haematologica. https://doi.org/10.1159/000539127

Vancouver

Barberio J, Lash TL, Nooka AK, Naimi AI, Patzer RE, Kim C. Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs. Acta Haematologica. 2024. doi:10.1159/000539127

BibTeX
@article{Barberio2024,
  author = {Barberio, Julie and Lash, Timothy L and Nooka, Ajay K and Naimi, Ashley I and Patzer, Rachel E and Kim, Christopher},
  title = {Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000539127}
}
Kostenlos starten →